Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Virology of Regdanvimab (CT-P59) in Mild SARS-CoV-2 Infection
NCT04593641Phase 1Completed
- Sponsor
- Celltrion
- Start
- Sep 2020
- Primary completion
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of regdanvimab in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Celltrion. Primary endpoints: Number of Patients With Treatment-Emergent Adverse Events at Day 14, Number of Patients With Treatment-Emergent Serious Adverse Events at Day 14 and 2 more. Started Sep 2020; status: completed.
02
Drugs
regdanvimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04593641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04593641.